corporate presentation february 2007 tomorrow s drugs today 2 21 page forward looking statements any in this are subject to a number of risks and uncertainties while represents management current judgement on the future direction company business actual results could differ materially from those anticipated these undertakes no obligation release publicly revisions reflect events or circumstances arising after date hereof 3 agenda 01 evotec overview 02 clinical cns pipeline evt 201 gaba modulator for insomnia 101 subtype selective nmda receptor antagonist 302 mao b inhibitor 03 partnerships 04 financials outlook 4 highlights z established biotech with powerful track record drug discovery development small molecule engine eur 65 m revenues cash generative attractive compounds blockbuster indications 75 fse listed public 5 machine target
